Hiba Graham

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 180 citations

Medicine, Infectious Diseases, Pharmacology +16

A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.

Kenneth E.L. McColl, A El-Nujumi, R S Chittajallu et al. · Gut · 1993 · 152 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +13

Performance of Creatinine and Cystatin C GFR Estimating Equations in an HIV-Positive Population on Antiretrovirals

Lesley A. Inker, Christina Wyatt, Rebecca Creamer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 88 citations · Full text

Medicine, Nephrology, Hiv Control +16

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Sharon A. Riddler, Michael F. Para, Constance A. Benson et al. · Clinical Infectious Diseases · 2020 · 74 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Kristen Andreatta, Madeleine Willkom, Ross Martin et al. · Journal of Antimicrobial Chemotherapy · 2019 · 62 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17